TEMODAR Drug Insight and Market Forecast - 2032

This “TEMODAR Drug Insight and Market Forecast - 2032” report provides comprehensive insights about TEMODAR for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the TEMODAR for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TEMODAR for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TEMODAR market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

The active pharmaceutical ingredient in TEMODAR/TEMODAL, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets tumoral tissues selectively; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. TEMODAR/TEMODAL was initially commercialized by Merck in different countries, whereas Baxter Oncology was responsible for manufacturing TEMODAR injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of temozolomide has also been approved by Double Bond Pharmaceuticals.

Dosage and administration
Administer TEMODAR either orally or intravenously once daily for 42 consecutive days during the concomitant phase with focal radiotherapy and then once daily on Days 1 to 5 of each 28-day cycle for 6 cycles during the maintenance phase.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TEMODAR description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on TEMODAR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TEMODAR research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TEMODAR.
• The report contains forecasted sales of TEMODAR for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for TEMODAR in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TEMODAR Analytical Perspective

In-depth TEMODAR Market Assessment

This report provides a detailed market assessment of TEMODAR for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

TEMODAR Clinical Assessment

The report provides the clinical trials information of TEMODAR for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TEMODAR dominance.
• Other emerging products for GBM are expected to give tough market competition to TEMODAR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TEMODAR in GBM.
• This in-depth analysis of the forecasted sales data of TEMODAR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TEMODAR in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of TEMODAR?
• What is the clinical trial status of the study related to TEMODAR in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TEMODAR development?
• What are the key designations that have been granted to TEMODAR for GBM?
• What is the forecasted market scenario of TEMODAR for GBM?
• What are the forecasted sales of TEMODAR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to TEMODAR for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

This product will be delivered within 2 business days.